Riverside Methodist Hospital, a not-for-profit, faith-based healthcare system in Columbus, Ohio, has implanted the first US patient with Cook Medical’s drug-eluting peripheral stent, designed for use in the above-the-knee femoropopliteal artery.
Coated with the drug paclitaxel, the Zilver PTX drug-eluting peripheral stent limits cell growth and prevents renarrowing of the artery over time.
The combination of the stent and paclitaxel has been shown to maintain arterial blood flow to the superficial femoral artery in seven out of ten patients up to 24 months after implantation.
The device has also been proven to reduce more than 50% of the need for follow-up procedures to reopen the artery, according to the company.
Riverside Methodist Hospital Centre for Critical Limb Care director Dr Gary Ansel said the device is considered to be the standard of PAD care in the US, as it provides prolonged patient benefit, when compared to the older peripheral arterial disease (PAD) treatments such as balloon angioplasty and bare metal stents.
"It was a great honor for my institution to be first to implant Cook Medical’s Zilver PTX as part of the stent’s commercial roll-out," Ansel said.
Cook Medical peripheral intervention division vice president and global leader Rob Lyles said; "The first commercial use of this stent represents what I think will be the start of a complete shift in the way physicians will treat PAD patients in this country."
In addition to the US, the Zilver PTX stent is available in 54 markets including the European Union, Brazil, Australia, Taiwan and Japan.
Image: Cook Medical’s Zilver PTX Drug-Eluting Peripheral Stent, which has been implanted in the first patient in the US. Photo: Courtesy of Cook Medical.